Pulmonary
SP-D is a defence
lectin promoting clearance of
viral infections.
SP-D is recognized to bind the S
protein of SARS-CoV and enhance phagocytosis. Moreover, systemic
SP-D is widely used as a
biomarker of alveolar integrity. We investigated the relation between plasma
SP-D, SARS-type
pneumonia and the SARS-specific
IgG response. Sixteen patients with SARS, 19 patients with community-acquired
pneumonia (CAP) (Streptococcus
pneumonia) and 16 healthy control subjects were enrolled in the study. Plasma
SP-D and anti-
SARS-CoV N protein IgG were measured using ELISA.
SP-D was significantly elevated in SARS-type
pneumonia [median (95% CI), 453 (379-963) ng/ml versus controls 218 (160-362) ng/ml, P < 0.05] like in patients with CAP.
SP-D significantly correlated with anti-
SARS-CoV N protein IgG (r(2) = 0.5995, P = 0.02). The possible re-emergence of SARS or SARS-like
infections suggests a need for minimal traumatic techniques for following the alveolar compartment, e.g. during testing of
antivirals. We suggest that monitoring systemic
SP-D may be useful in monitoring the alveolar integrity in SARS-type
pneumonia. The significant correlation between plasma
SP-D and anti-SARS-CoV-specific
antibodies support the role for
SP-D in interlinking innate and adaptive immune pathways.